BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niedeggen C, Singer S, Groth M, Petermann-Meyer A, Röth A, Schrezenmeier H, Höchsmann B, Brümmendorf TH, Panse J. Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III. Ann Hematol 2019;98:1547-59. [PMID: 31115593 DOI: 10.1007/s00277-019-03681-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Weisshaar K, Ewald H, Halter J, Gerull S, Schönfeld S, Senft Y, Martinez M, Leuppi-Taegtmeyer A, Khanna N, Maier B, Risitano A, Peffault de Latour R, Tichelli A, Passweg J, Drexler B. Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH). Orphanet J Rare Dis 2020;15:249. [PMID: 32943103 DOI: 10.1186/s13023-020-01532-3] [Reference Citation Analysis]
2 Schwartz CE, Stark RB, Borowiec K, Nolte S, Myren KJ. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria. Orphanet J Rare Dis 2021;16:389. [PMID: 34526067 DOI: 10.1186/s13023-021-02016-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sakai K. Even mild hemolysis in paroxysmal nocturnal hemoglobinuria could severely compromise the quality of life due to long-term sustained intolerant fatigue. Leuk Res Rep 2020;14:100224. [PMID: 33083224 DOI: 10.1016/j.lrr.2020.100224] [Reference Citation Analysis]
4 Panse J. [Diagnosis and Therapy of aplastic anemia - update 2021]. Dtsch Med Wochenschr 2021;146:451-4. [PMID: 33780990 DOI: 10.1055/a-1169-0902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Krishnan S, Sarda S, Kunzweiler C, Wu M, Sundaresan S, Huynh L, Duh MS, Escalante CP. Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria. Adv Ther 2022;39:1959-75. [PMID: 35316499 DOI: 10.1007/s12325-022-02111-7] [Reference Citation Analysis]
6 Daly RP, Jalbert JJ, Keith S, Symonds T, Shammo J. A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ. J Patient Rep Outcomes 2021;5:102. [PMID: 34581910 DOI: 10.1186/s41687-021-00376-0] [Reference Citation Analysis]